RT Journal Article
SR Electronic
T1 Immunogenicity and crossreactivity of antibodies to SARS-CoV-2 nucleocapsid protein
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.19.20248551
DO 10.1101/2020.12.19.20248551
A1 Carlota Dobaño
A1 Rebeca Santano
A1 Alfons Jiménez
A1 Marta Vidal
A1 Jordi Chi
A1 Natalia Rodrigo Melero
A1 Matija Popovic
A1 Rubén López-Aladid
A1 Laia Fernández-Barat
A1 Marta Tortajada
A1 Francisco Carmona-Torre
A1 Gabriel Reina
A1 Antoni Torres
A1 Alfredo Mayor
A1 Carlo Carolis
A1 Alberto L. García-Basteiro
A1 Ruth Aguilar
A1 Gemma Moncunill
A1 Luis Izquierdo
YR 2020
UL http://medrxiv.org/content/early/2020/12/22/2020.12.19.20248551.abstract
AB COVID-19 patients elicit strong responses to the nucleocapsid (N) protein of SARS-CoV-2 but binding antibodies are also detected in prepandemic individuals, indicating potential crossreactivity with common cold human coronaviruses (HCoV) and questioning its utility in seroprevalence studies. We investigated the immunogenicity of the full-length and shorter fragments of the SARS-CoV-2 N protein, and the crossreactivity of antibodies with HCoV. We indentified a C-terminus region in SARS-CoV2 N of minimal sequence homology with HCoV that was more specific and highly immunogenic. IgGs to the full-length SARS-CoV-2 N also recognised N229E N, and IgGs to HKU1 N recognised SARS-CoV-2 N. Crossreactivity with SARS-CoV-2 was stronger for alpha-rather than beta-HCoV despite having less sequence identity, revealing the importance of conformational recognition. Higher preexisting IgG to OC43 N correlated with lower IgG to SARS-CoV-2 in rRT-PCR negative individuals, reflecting less exposure and indicating a potential protective association. Antibodies to SARS-CoV-2 N were higher in patients with more severe and longer symptoms and in females. IgGs remained stable for at least 3 months, while IgAs and IgMs declined faster. In conclusion, N is a primary target of SARS-CoV-2-specific and HCoV crossreactive antibodies, both of which may affect the acquisition of immunity to COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe assays development and sample collection were performed with internal funds from the investigators groups and institutions. GM had the support of the Department of Health, Catalan Government (SLT006/17/00109). JC and LI are supported by SAF2016-76080-R grant from the Spanish Ministry of Economy (AEI/FEDER, UE) and by PID2019-110810RB-I00 grant from the Spanish Ministry of Science & Innovation to LI. AT and LFB received support from Departament General de Recerca i Innovacio en Salut (GENCAT-DGRIS-COVID19), CB 06/06/0028/CIBER de enfermedades respiratorias- Ciberes, ISCIII (FI19/00090 awarded to RLA) and IDIBAPS group 2.603. ISGlobal receives support from the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa 2019-2023 Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA ProgramAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocols and informed consent forms were approved by the Institutional Review Board at Hospital Clinic in Barcelona (Refs. CEIC-7455 and HCB/2020/0336) or Universidad de Navarra (Ref. UN/2020/067) prior to study implementation.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request to the corresponding authors